Loading clinical trials...
Loading clinical trials...
A Phase I Study of B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells in Combination With JSMD194, a Small Molecule Inhibitor of Gamma Secretase, in Patients With Relapsed or Persistent Multiple Myeloma
Conditions
Interventions
BCMA-specific CAR-expressing T Lymphocytes
Cyclophosphamide
+4 more
Locations
1
United States
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States
Start Date
May 23, 2018
Primary Completion Date
April 20, 2022
Completion Date
April 20, 2022
Last Updated
January 8, 2024
NCT05312255
NCT04508790
NCT04640779
NCT05288062
NCT02765854
NCT05191472
Lead Sponsor
Fred Hutchinson Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions